IDEXX Laboratories (IDXX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $4.27
- EPS estimate
- $3.94
- EPS surprise
- +8.28%
- Revenue surprise
- +1.36%
- Revenue
- $1.2B
- Revenue estimate
- $1.2B
- Reported
- Aug 4, 2026
IDEXX Laboratories reported Q2 2026 results on August 4, 2026. Earnings per share came in at $4.27, ahead of the $3.94 estimate by 8.28%. Revenue was $1.2 billion, 1.36% above the consensus. Compared with Q2 2025, EPS rose about 18% from $3.63, and revenue grew from $1.1 billion. Both figures were the highest in the table.
The longer record shows steady growth. Annual EPS rose every year, from $8.03 in 2022 to $10.07 in 2023, $10.67 in 2024 and $13.07 in 2025, about 63% over three years. The first half of 2026 adds up to $7.74, about 17% more than the same period a year earlier. Quarterly revenue has climbed from $801.1 million in Q4 2021, the low in the table. Over the last 20 quarters, IDEXX beat the EPS estimate 18 times. The two misses were Q2 2022, at 0.13% below, and Q2 2024, at 15.41% below. The latest eight quarters were all beats.
IDEXX reported Q3 between October 31 and November 3 in each of the past five years. That points to the turn of October and November 2026 for the next report. It will be compared with Q3 2025's $3.40 per share.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $3.94 | $4.27 | +8.28% | $1.2B | SEC |
| Q1 2026 | May 5, 2026 | $3.41 | $3.47 | +1.74% | $1.1B | SEC |
| Q4 2025 | Feb 2, 2026 | $2.93 | $3.08 | +5.00% | $1.1B | SEC |
| Q3 2025 | Nov 3, 2025 | $3.14 | $3.40 | +8.35% | $1.1B | SEC |
| Q2 2025 | Aug 4, 2025 | $3.30 | $3.63 | +9.93% | $1.1B | SEC |
| Q1 2025 | May 1, 2025 | $2.85 | $2.96 | +3.93% | $998.4M | SEC |
| Q4 2024 | Feb 3, 2025 | $2.40 | $2.62 | +9.04% | $954.3M | SEC |
| Q3 2024 | Oct 31, 2024 | $2.68 | $2.80 | +4.46% | $975.5M | SEC |
| Q2 2024 | Aug 6, 2024 | $2.88 | $2.44 | −15.41% | $1.0B | SEC |
| Q1 2024 | May 1, 2024 | $2.71 | $2.81 | +3.60% | $964.1M | SEC |
| Q4 2023 | Feb 5, 2024 | $2.12 | $2.32 | +9.22% | $901.6M | SEC |
| Q3 2023 | Nov 1, 2023 | $2.37 | $2.53 | +6.72% | $915.5M | SEC |
| Q2 2023 | Aug 1, 2023 | $2.47 | $2.67 | +7.90% | $943.6M | SEC |
| Q1 2023 | May 2, 2023 | $2.42 | $2.55 | +5.30% | $900.2M | SEC |
| Q4 2022 | Feb 6, 2023 | $1.92 | $2.05 | +6.57% | $828.6M | SEC |
| Q3 2022 | Nov 1, 2022 | $2.05 | $2.15 | +4.87% | $841.7M | SEC |
| Q2 2022 | Aug 2, 2022 | $1.56 | $1.56 | −0.13% | $860.5M | SEC |
| Q1 2022 | May 4, 2022 | $2.25 | $2.27 | +0.99% | $836.5M | SEC |
| Q4 2021 | Feb 2, 2022 | $1.72 | $1.89 | +9.99% | $801.1M | SEC |
| Q3 2021 | Nov 2, 2021 | $1.91 | $2.03 | +6.02% | $810.4M | SEC |
Quarterly revenue
Frequently asked questions
When did IDEXX Laboratories (IDXX) last report earnings?
IDEXX Laboratories last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did IDXX beat earnings estimates?
Yes. IDEXX Laboratories reported EPS of $4.27 for Q2 2026 against a $3.94 estimate — a 8.28% beat.
How much revenue did IDXX report last quarter?
IDEXX Laboratories reported $1.2B in revenue for Q2 2026, against a consensus estimate of $1.2B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.